The share of healthcare investment dollars going to early stage deals dropped sharply in the first quarter of this year to its lowest level in five quarters.
In the first quarter of 2011, just 1 percent of healthcare venture deals involved seed-stage companies, according to a report from New York research firm CB Insights. That compares with 6 percent of the deals the prior quarter and 3 percent in last year’s first quarter.
At the same time fewer deals involved seed-stage companies, the overall number of healthcare deals dropped 13 percent to 150 compared to both the first and last quarters of 2010. Each of those quarters featured 173 healthcare venture deals, according to the report.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CB Insights co-founder Anand Sanwal attributed the “malaise” in the healthcare venture investment market to three primary factors: biomedical investments are often “capital intensive,” which turns off some VCs; the long time horizons it often takes for biomedical companies to exit; and a lack of many recent exits for health firms.
Industry insiders would likely say the downward trend in seed deals illustrates the need to find creative ways — such as state assistance — of getting more dollars to early stage biomedical firms as they navigate the so-called “valley of death” between startup and getting a product on the market. Angel investors in some cases can fill that role, but a recent report from the University of New Hampshire’s Center for Venture Research shows that angels, too, are decreasing the share of investment they put into early stage deals.
“This decrease in seed/startup stage and first sequence investing is of concern,” said Jeffrey Sohl, the center’s director, according to peHub.
One positive trend the CB Insights report showed for early stage health investing is that, at $2 million, median deal size grew to its greatest level in at least five quarters. That’s a huge increase over the first quarter of 2010, when the median early stage deal size was $400,000.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
At a little less than $1.6 billion, the overall dollar value of healthcare deals in the first quarter was up 11 percent year-over-year and was flat when compared with the prior quarter.
As always, California and Massachusetts dominate the healthcare venture investing industry. California companies pulled in a whopping 45 percent of all healthcare investment dollars, while Massachusetts contributed 19 percent. North Carolina was a distant third at 6 percent.
